US Patent

US9744129 — Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain

Formulation · Assigned to AcelRx Pharmaceuticals Inc · Expires 2027-01-05 · 1y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects small volume oral transmucosal dosage forms containing sufentanil citrate for the treatment of pain.

USPTO Abstract

Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.

Drugs covered by this patent

sufentanil-citrate (SUFENTANIL CITRATE)

Patent Metadata

Patent number: US9744129
Jurisdiction: US
Classification: Formulation
Expires: 2027-01-05
Drug substance claim: No
Drug product claim: Yes
Assignee: AcelRx Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.